Santen Pharmaceutical
As of the edition of 20 October 2026, Santen Pharmaceutical runs 31 drugs, 18 of them marketed; it is on route A at 2 targets and on route B at 10 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 18 |
| Active | 1 |
| Went quiet | 7 |
| Stopped | 2 |
| Status not established | 3 |
| Total | 31 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Dexamethasone | none listed | 5 |
| Methotrexate | none listed | 2 |
| Cyclosporine | none listed | 3 |
| Levofloxacin anhydrous | none listed | 0 |
| Timolol | none listed | 5 |
| Atropine | none listed | 12 |
| Latanoprost | none listed | 5 |
| Oxymetazoline | none listed | 13 |
| Dorzolamide | none listed | 2 |
| Netarsudil | Ends 2034 (patent) | 6 |
| Diquafosol | none listed | 3 |
| Tafluprost | none listed | 2 |
| Methacholine | none listed | 3 |
| Epinastine | none listed | 1 |
| Omidenepag isopropyl | Ends 2035 (patent) | 1 |
| Spinosad | none listed | 0 |
| Sepetaprost | none listed | 0 |
| Pemirolast | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 2 targets, route B at 10 targets.
All 12 rows on route A or B
In the product12 company-target rows on route A or B; 9 are not shown here, and no score is.
See all 12 targets where Santen Pharmaceutical needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Eye: 40 trials led
- Immune system: 2 trials led
- Inherited and neonatal: 1 trials led